FDA approves landmark pancreatic cancer drug that's shown to improve survival

The FDA has approved daraxonrasib, a landmark first-of-a-kind pill designed to treat pancreatic cancer. Clinical studies demonstrate that this new medication significantly improves patient survival rates compared to traditional treatments. Specifically, patients receiving daraxonrasib achieved a median survival of 13.2 months, whereas those receiving chemotherapy lived for a median of 6.7 months. This approval marks a significant advancement in oncology, offering a new therapeutic option to extend the lives of patients battling this disease.